Lyra Therapeutics, Inc.LYRANASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank83
3Y CAGR+13.8%
5Y CAGR+29.5%
Year-over-Year Change
Research and development spending
3Y CAGR
+13.8%/yr
Annual compound
5Y CAGR
+29.5%/yr
Recent deceleration
Percentile
P83
Within normal range
vs 5Y Ago
3.6x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| 2024 | $43.77M | -8.9% |
| 2023 | $48.03M | +23.8% |
| 2022 | $38.80M | +30.7% |
| 2021 | $29.69M | +137.1% |
| 2020 | $12.52M | +4.1% |
| 2019 | $12.03M | +141.8% |
| 2018 | $4.97M | - |